Animal models of anaphylaxis

Current Opinion in Allergy and Clinical Immunology

Volumn 7, Issue 4, 2007, Pages 355-359

  Nauta, Alma ^a   Knippels, Leon ^a   Garssen, Johan ^b   Redegeld, Frank ^b  

^a NUMICO RESEARCH   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Anaphylaxis; Hypersensitivity; Immunoglobulin free light chains; Insect allergy; Insect venom; Mast cells

Indexed keywords

ANTIGEN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN LIGHT CHAIN;

ALLERGIC REACTION; ANAPHYLAXIS; ANTIGEN SPECIFICITY; DISEASE MODEL; DISEASE SEVERITY; FOOD ALLERGY; IMMUNOGLOBULIN PRODUCTION; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; INFLAMMATORY DISEASE; INFLAMMATORY INFILTRATE; INSECT ALLERGY; MAST CELL; MAST CELL DEGRANULATION; MILK ALLERGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SENSITIZATION; T LYMPHOCYTE ACTIVATION;

ANAPHYLAXIS; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ARTHROPOD VENOMS; FOOD HYPERSENSITIVITY; GUINEA PIGS; IMMUNOGLOBULIN LIGHT CHAINS; INSECT BITES AND STINGS; MAST CELLS; MICE; MODELS, ANIMAL; RATS;

EID: 34447345688     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e32825ea543     Document Type: Review

References (54)

1. Matsuda T, Matsubara T, Hino S. Immunogenic and allergenic potentials of natural and recombinant innocuous proteins. J Biosci Bioeng 2006; 101:203-211.
2. Winkler B, Bolwig C, Seppala U, et al. Allergen-specific immunosuppression by mucosal treatment with recombinant Ves v 5, a major allergen of Vespula vulgaris venom, in a murine model of wasp venom allergy. Immunology 2003; 110:376-385.
3. Chen YL, Simons FE, Peng Z. A mouse model of mosquito allergy for study of antigen-specific IgE and IgG subclass responses, lymphocyte proliferation, and IL-4 and IFN-gamma production. Int Arch Allergy Immunol 1998; 116:269-277.
4. Dudler T, Machado DC, Kolbe L, et al. A link between catalytic activity, IgE-independent mast cell activation, and allergenicity of bee venom phospholipase A2. J Immunol 1995; 155:2605-2613.
5. King TP, Jim SY, Wittkowski KM. Inflammatory role of two venom components of yellow jackets (Vespula vulgaris): a mast cell degranulating peptide mastoparan and phospholipase A1. Int Arch Allergy Immunol 2003; 131:25-32.
6. Li XM, Serebrisky D, Lee SY, et al. A murine model of peanut anaphylaxis: T- and B-cell responses to a major peanut allergen mimic human responses. J Allergy Clin Immunol 2000; 106:150-158.
7. Knippels LM, Penninks AH, Spanhaak S, et al. Oral sensitization to food proteins: a Brown Norway rat model. Clin Exp Allergy 1998; 28:368-375.
8. Piacentini GL, Bertolini A, Spezia E, et al. Ability of a new infant formula prepared from partially hydrolyzed bovine whey to induce anaphylactic sensitization: evaluation in a guinea pig model. Allergy 1994; 49:361-364.
9. Helm RM. Food allergy animal models: an overview. Ann N Y Acad Sci 2002; 964:139-150.
10. Knippels LM, Penninks AH, van Meeteren M, et al. Humoral and cellular immune responses in different rat strains on oral exposure to ovalbumin. Food Chem Toxicol 1999; 37:881-888.
11. Ito K, Inagaki-Ohara K, Murosaki S, et al. Murine model of IgE production with a predominant Th2-response by feeding protein antigen without adjuvants. Eur J Immunol 1997; 27:3427-3437.
12. Li XM, Schofield BH, Huang CK, et al. A murine model of IgE-mediated cow's milk hypersensitivity. J Allergy Clin Immunol 1999; 103:206-214.
13. Dearman RJ, Kimber I. A mouse model for food allergy using intraperitoneal sensitization. Methods 2007; 41:91-98.
14. Buchanan BB, Frick OL. The dog as a model for food allergy. Ann N Y Acad Sci 2002; 964:173-183.
15. Helm RM, Furuta GT, Stanley JS, et al. A neonatal swine model for peanut allergy. J Allergy Clin Immunol 2002; 109:136-142.
16. Chen CC, Grimbaldeston MA, Tsai M, et al. Identification of mast cell progenitors in adult mice. Proc Natl Acad Sci U S A 2005; 102:11408-11413.
17. Arinobu Y, Iwasaki H, Gurish MF, et al. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc Natl Acad Sci U S A 2005; 102:18105-18110.
18. Okayama Y, Kawakami T. Development, migration, and survival of mast cells. Immunol Res 2006; 34:97-115.
19. Rottem M, Hull G, Metcalfe DD. Demonstration of differential effects of cytokines on mast cells derived from murine bone marrow and peripheral blood mononuclear cells. Exp Hematol 1994; 22:1147-1155.
20. Ryan JJ, Kashyap M, Bailey D, et al. Mast cell homeostasis: a fundamental aspect of allergic disease. Crit Rev Immunol 2007; 27:15-32.
21. Theoharides TC, Kalogeromitros D. The critical role of mast cells in allergy and inflammation. Ann N Y Acad Sci 2006; 1088:78-99. Concise review describing the triggers for mast cell activation, mediators released by mast cells and the role of mast cells in different pathologies.
22. Oliveira SH, Hogaboam CM, Berlin A, et al. SCF-induced airway hyperreactivity is dependent on leukotriene production. Am J Physiol Lung Cell Mol Physiol 2001; 280:L1242-L1249.
23. Karimi K, Kool M, Nijkamp FP, et al. Substance P can stimulate prostaglandin D2 and leukotriene C4 generation without granule exocytosis in murine mast cells. Eur J Pharmacol 2004; 489:49-54.
24. Mortaz E, Redegeld FA, Dunsmore K, et al. Stimulation of cysteinyl leukotriene production in mast cells by heat shock and acetylsalicylic acid. Eur J Pharmacol 2007; 561:214-219.
25. Ihle JN, Keller J, Oroszlan S, et al. Biologic properties of homogeneous interleukin 3. I: Demonstration of WEHI-3 growth factor activity, mast cell growth factor activity, p cell-stimulating factor activity, colony-stimulating factor activity, and histamine-producing cell-stimulating factor activity. J Immunol 1983; 131:282-287.
26. Malbec O, Roget K, Schiffer C, et al. Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type mouse mast cells. J Immunol 2007; 178:6465-6475.
27. Sur R, Cavender D, Malaviya R. Different approaches to study mast cell functions. Int Immunopharmacol 2007; 7:555-567.
28. Karimi K, Redegeld FA, Heijdra B, et al. Stem cell factor and interleukin-4 induce murine bone marrow cells to develop into mast cells with connective tissue type characteristics in vitro. Exp Hematol 1999; 27:654-662.
29. Tsuji K, Zsebo KM, Ogawa M. Murine mast cell colony formation supported by IL-3, IL-4, and recombinant rat stem cell factor, ligand for c-kit. J Cell Physiol 1991; 148:362-369.
30. Yamada N, Matsushima H, Tagaya Y, et al. Generation of a large number of connective tissue type mast cells by culture of murine fetal skin cells. J Invest Dermatol 2003; 121:1425-1432.
31. Valent P, Spanblochl E, Sperr WR, et al. Induction of differentiation of human mast cells from bone marrow and peripheral blood mononuclear cells by recombinant human stem cell factor/kit-ligand in long-term culture. Blood 1992; 80:2237-2245.
32. Wang XS, Lau HY. Histamine release from human buffy coat-derived mast cells. Int Immunopharmacol 2007; 7:541-546.
33. Wang XS, Yip KH, Sam SW, et al. Buffy coat preparation is a convenient source of progenitors for culturing mature human mast cells. J Immunol Methods 2006; 309:69-74.
34. Theoharides TC, Kempuraj D, Tagen M, et al. Human umbilical cord blood-derived mast cells: a unique model for the study of neuro-immuno-endocrine interactions. Stem Cell Rev 2006; 2:143-154.
35. Bischoff SC. Role of mast cells in allergic and nonallergic immune responses: comparison of human and murine data. Nat Rev Immunol 2007; 7:93-104. Review describing the recent advances in human mast cell biology and comparing the findings made with human and murine mast cells.
36. Grimbaldeston MA, Chen CC, Piliponsky AM, et al. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am J Pathol 2005; 167:835-848.
37. Grimbaldeston MA, Metz M, Yu M, et al. Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. Curr Opin Immunol 2006; 18:751-760. This article focuses on the role of mast cells in the sensitization phase of an allergic response, the effector phase, late phase reaction and its role during chronic inflammation.
38. Finkelman FD, Rothenberg ME, Brandt EB, et al. Molecular mechanisms of anaphylaxis: lessons from studies with murine models. J Allergy Clin Immunol 2005; 115:449-457.
39. Peng Z, Yang M, Simons FE. Immunologic mechanisms in mosquito allergy: correlation of skin reactions with specific IgE and IgG antibodies and lymphocyte proliferation response to mosquito antigens. Ann Allergy Asthma Immunol 1996; 77:238-244.
40. Xu X, Yang H, Yu H, et al. The mastoparanogen from wasp. Peptides 2006; 27:3053-3057.
41. Dubois AE. Mastocytosis and Hymenoptera allergy. Curr Opin Allergy Clin Immunol 2004; 4:291-295.
42. Rueff F, Placzek M, Przybilla B. Mastocytosis and Hymenoptera venom allergy. Curr Opin Allergy Clin Immunol 2006; 6:284-288.
43. Metz M, Piliponsky AM, Chen CC, et al. Mast cells can enhance resistance to snake and honeybee venoms. Science 2006; 313:526-530. This study describes that mast cells can significantly reduce the morbidity and mortality induced by honeybee venom. It was found that the release of carboxypeptidase A is likely responsible for the breakdown of venom components such as endothelin-like proteins.
44. Maurer M, Wedemeyer J, Metz M, et al. Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature 2004; 432:512-516.
45. Ohtsuka E, Kawai S, Ichikawa T, et al. Roles of mast cells and histamine in mosquito bite-induced allergic itch-associated responses in mice. Jpn J Pharmacol 2001; 86:97-105.
46. Depinay N, Hacini F, Beghdadi W, et al. Mast cell-dependent down-regulation of antigen-specific immune responses by mosquito bites. J Immunol 2006; 176:4141-4146. In this study it is shown that mosquito bites can activate mast cells and results in local production of MIP-2 in the skin and IL-10 in the draining lymph nodes. The IL-10 production ultimately leads to the downregulation of antigen-specific T cell responses.
47. + produce the mast cell growth and activating factor IL-9, resulting in recruitment and activation of mast cells in tolerant tissue. In turn, mast cells seem responsible for the release of immunosuppressive mediators.
48. Strait RT, Morris SC, Yang M, et al. Pathways of anaphylaxis in the mouse. J Allergy Clin Immunol 2002; 109:658-668.
49. Strait RT, Morris SC, Finkelman FD. IgG-blocking antibodies inhibit IgEmediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 2006; 116:833-841. This study shows that IgG blocking antibodies can completely downregulate IgE-mediated anaphylaxis without the induction of anaphylaxis through an alternative pathway (FcγRIII) provided that the IgG antibody concentration is high and the allergen dose is low.
50. Redegeld FA, van der Heijden MW, Kool M, et al. Immunoglobulin-free light chains elicit immediate hypersensitivity-like responses. Nat Med 2002; 8:694-701.
51. Redegeld FA, Nijkamp FP. Immunoglobulin free light chains and mast cells: pivotal role in T-cell-mediated immune reactions? Trends Immunol 2003; 24:181-185.
52. Kraneveld AD, Kool M, van Houwelingen AH, et al. Elicitation of allergic asthma by immunoglobulin free light chains. Proc Natl Acad Sci U S A 2005; 102:1578-1583.
53. van Houwelingen AH, Kaczynska K, Kraneveld AD, et al. Topical application of F991, an immunoglobulin free light chain antagonist, prevents development of contact sensitivity in mice. Clin Exp Allergy 2007; 37:270-275.
54. van der Heijden M, Kraneveld A, Redegeld F. Free immunoglobulin light chains as target in the treatment of chronic inflammatory diseases. Eur J Pharmacol 2006; 533:319-326. Review of the various biological properties of immunoglobulin free light chains with a special focus on their possible role in inflammatory diseases.